You Dokyoung S, Mardian Aram S, Darnall Beth D, Chen Chwen-Yuen A, De Bruyne Korina, Flood Pamela D, Kao Ming-Chih, Karnik Anita D, McNeely Jennifer, Porter Joel G, Schwartz Robert P, Stieg Richard L, Mackey Sean C
Department Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Palo Alto, CA, United States.
Department of Family, Community and Preventive Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.
Front Med (Lausanne). 2021 Mar 31;8:591201. doi: 10.3389/fmed.2021.591201. eCollection 2021.
Growing concerns about the safety of long-term opioid therapy and its uncertain efficacy for non-cancer pain have led to relatively rapid opioid deprescribing in chronic pain patients who have been taking opioid for years. To date, empirically supported processes for safe and effective opioid tapering are lacking. Opioid tapering programs have shown high rates of dropouts and increases in patient distress and suicidal ideation. Therefore, safe strategies for opioid deprescribing that are more likely to succeed are urgently needed. In response to this demand, the EMPOWER study has been launched to examine the effectiveness of behavioral medicine strategies within the context of patient-centered opioid tapering in outpatient settings (https://empower.stanford.edu/). The EMPOWER protocol requires an efficient process for ensuring that collaborative opioid tapering would be offered to the most appropriate patients while identifying patients who should be offered alternate treatment pathways. As a first step, clinicians need a screening tool to identify patients with Opioid Use Disorder (OUD) and to assess for OUD severity. Because such a tool is not available, the study team composed of eight chronic pain and/or addiction experts has extended a validated screening instrument to develop a brief and novel consensus screening tool to identify OUD and assess for OUD severity for treatment stratification. Our screening tool has the potential to assist busy outpatient clinicians to assess OUD among patients receiving long-term opioid therapy for chronic pain.
对长期阿片类药物治疗安全性的日益担忧及其对非癌性疼痛疗效的不确定性,导致多年来一直服用阿片类药物的慢性疼痛患者的阿片类药物减药相对迅速。迄今为止,缺乏经实证支持的安全有效的阿片类药物减量流程。阿片类药物减量计划显示出高辍学率以及患者痛苦和自杀意念的增加。因此,迫切需要更有可能成功的安全的阿片类药物减药策略。为了回应这一需求,已启动了EMPOWER研究,以检验在门诊环境中以患者为中心的阿片类药物减量背景下行为医学策略的有效性(https://empower.stanford.edu/)。EMPOWER方案要求有一个高效的流程,以确保将协作性阿片类药物减量提供给最合适的患者,同时识别应提供替代治疗途径的患者。作为第一步,临床医生需要一种筛查工具来识别患有阿片类药物使用障碍(OUD)的患者并评估OUD的严重程度。由于没有这样的工具,由八位慢性疼痛和/或成瘾专家组成的研究团队扩展了一种经过验证的筛查工具,以开发一种简短而新颖的共识筛查工具,用于识别OUD并评估OUD严重程度以进行治疗分层。我们的筛查工具有可能帮助忙碌的门诊临床医生评估接受长期阿片类药物治疗慢性疼痛的患者中的OUD。